NCT06534658 Study on Multimodal Imaging and Molecular Imaging Techniques in Degenerative Dementia
| NCT ID | NCT06534658 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ruijin Hospital |
| Condition | Alzheimer Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2020-07-30 |
| Primary Completion | 2029-07-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2020-07-30 with a primary completion date of 2029-07-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This project is a multicenter observational study that establishes a longitudinal cohort of patients with Alzheimer's disease and other dementias based on neuroimaging, molecular imaging, biological and digital markers to explore new solutions such as dementia disease mechanism, diagnosis, condition evaluation, and prognosis assessment.
Eligibility Criteria
Inclusion Criteria: * Patients aged ≥50 and ≤85 years old, male or female; * Meet the diagnostic criteria for dementia or MCI; * Neuropsychological score: MMSE 15-28 points, CDR ≤ 1 point; ④ Patients and their families are informed and sign the informed consent form Exclusion Criteria: * The presence of other neurological diseases that may cause brain dysfunction (such as depression, brain tumors, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.); * The presence of other systemic diseases that may cause cognitive impairment (such as liver dysfunction, renal dysfunction, thyroid dysfunction, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.); * Suffering from a disease that makes it impossible to cooperate with cognitive examinations; * The presence of contraindications to MRI; * The presence of mental and neurological retardation; * Refusing to draw blood; * Refusing to sign the informed consent form.
Contact & Investigator
Gang Wang, PhD. MD.
PRINCIPAL INVESTIGATOR
RenJi Hospital
Frequently Asked Questions
Who can join the NCT06534658 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 85 Years, studying Alzheimer Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06534658 currently recruiting?
Yes, NCT06534658 is actively recruiting participants. Contact the research team at jt_wang@sjtu.edu.cn for enrollment information.
Where is the NCT06534658 trial being conducted?
This trial is being conducted at Beijing, China, Hanzhong, China, Cangzhou, China, Shijiazhuang, China and 4 additional locations.
Who is sponsoring the NCT06534658 clinical trial?
NCT06534658 is sponsored by Ruijin Hospital. The principal investigator is Gang Wang, PhD. MD. at RenJi Hospital. The trial plans to enroll 1,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.